Following teens and adults with atopic dermatitis as they start or change systemic treatment
Follows adolescents and adults with atopic dermatitis starting or switching systemic treatments.
Plain-language title generated from the registry record
Registry title: This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
Key facts
- Where
- Abu Dhabi, Al Karama, and Dubai, United Arab EmiratesSee the 4 sites
Where in United Arab Emirates
- Mediclinic Hospital, AUH-Site Number: 7840004Abu Dhabi, United Arab EmiratesTaking people
- NMC Specialty Hospital-Site Number : 7840002Abu Dhabi, United Arab EmiratesTaking people
- Dr Joseph Polyclinic Amber Clinic-Site Number: 7840005Al Karama, United Arab EmiratesTaking people
- Dermatology and Aesthetic Center Rashid Hospital-Site Number : 7840003Dubai, United Arab EmiratesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanofi
- Trial code
- NCT07290803
- Record updated
- 2 November 2026
- Original description
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.Read full original descriptionShow less
Atopic Dermatitis Disease Registry of Adult and Adolescent Patients Initiating or Switching Systemic Treatments
The objectives of this prospective non-interventional study are to characterize the existing unmet needs across the spectrum of atopic dermatitis (AD), enhance the understanding of the patient journey, and evaluate the safety and clinical outcomes of systemic AD treatments in a real-world setting. Additionally, patient-specific factors (such as age, skin color, AD flare triggers, previous treatment responses, comorbid conditions, and the extent and site of lesions) will be assessed to better characterize the impact on the treatment journey across a broad age range and diverse geographic regions.
The study will be conducted across 10 countries in 4 different geographical regions, with a follow-up period of 5 years.
Inclusion: Patients aged more than or equal to (≥) 12 years at the time of consent; Confirmed diagnosis of AD, of any severity, according to the Investigator's assessment as aligned with International Classification of Diseases 10th revision (ICD-10) code of L20; Prescribed and scheduled to initiate any systemic treatment for AD (including but not limited to biologics, oral Janus kinase (JAK) inhibitors, cyclosporine, azathioprine, methotrexate, mycophenolate mofetil); Signed informed consent for registry participation by the patient or parent/legal representative and assent by the patient appropriate to the patient's age, including willingness to participate in long-term follow-up.
Exclusion: Concurrent participation in an interventional clinical trial that administers an investigational drug that modifies patient care; Insufficient understanding of the study by the patient and/or parent/guardian; The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.